Table 2.

CAFs, MVD, and LVD in 93 patients with lung adenocarcinoma and their correlation with clinical pathological variables

	N	CAFs	P	HR (95%CI)	MVD	P	HR (95%CI)	LVD	P	HR (95%CI)
Gender
Men	60		1.000	1.000 (0.406‐2.462)		0.219	1.759 (0.714‐4.331)		0.170	1.864 (0.765‐4.538)
Women	33
Age
≥60	55		0.007	1.065 (1.017‐1.114)		0.000	1.138 (1.071‐1.209)		0.013	1.059 (1.012‐1.107)
<60	38
Location
Central	11		0.821	1.164 (0.313‐4.323)		0.626	0.729 (0.205‐2.592 )		0.821	1.164 (0.313‐4.323)
Peripheral	82
Diameter
>3 cm	65		0.000	12.273 (4.315‐34.906)		0.001	14.258 (3.124‐65.083)		0.000	16.500 (5.554‐49.021)
≤3 cm	28
Differentiation grade
High	18		0.007	1		0.001	1		0.014	1
Medium	53		0.048	3.056 (1.012‐9.226)		0.998	637687425.543 (0.000‐)		0.190	2.062 (0.698‐6.091)
Poor	22		0.002	15.714 (2.772‐89.098)		0.998	33924971038.902 (0.000‐)		0.004	26.250 (2.877‐239.537)
TNM staging
I	27		0.000	1		0.000	1		0.000	1
II	35		0.000	9.643 (3.000‐30.995)		0.179	3.125 (0.593‐16.459)		0.000	10.111 (3.100‐32.980)
IIIa	19		0.000	15.238 (3.387‐68.553)		0.000	46.875 (7.640‐287.595)		0.000	63.00 (6.921‐573.503)
IIIb	12		0.998	4615642473.783 (0.000‐)		0.998	20193435809.473 (0.000‐)		0.998	5654162030.960 (0.000‐)
Lymphatic metastasis
With	58		0.005	3.665 (1.482‐9.066)		0.001	14.258 (3.124‐65.083)		0.001	4.552 (1.815‐11.419)
Without	35
Smoking history
With	47		0.558	0.772 (0.325‐1.834)		0.731	1.158 (0.502‐2.669)		0.306	0.635 (0.266‐1.516)
Without	46

CAFs, cancer‐associated fibroblasts; LVD, lymphatic vessel density; MVD, microvessel density.